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Summary The human proto-oncogene INT2 (homologous to the mouse INT2 gene, implicated in proviral
induced mammary carcinoma) has been mapped to chromosome q13 and found to share band localisation
with, among others, the HSTJ proto-oncogene. Both genes are members of the fibroblast growth factor
family. In the present study, coamplification (2-15 copies) of the INT2/HSTJ genes was found in 27 (9%) of
311 invasive human breast carcinomas using slot blot and Southern blot analyses. Amplification was not
correlated to tumour size, axillary lymph node status or stage of disease, neither to patient age nor
menopausal status. However, 26 (96%) of the 27 amplified tumours were, often strongly, Oestrogen receptor
positive compared to 65% of the unamplified cases (P = 0.001). These findings are in sharp contrast to the
strong correlations of HER-2/neu proto-oncogene amplification with advanced stage and steroid receptor
negativity, previously observed in the same series of tumours. Patients with INT2/HSTI amplified breast
cancer had a significantly shorter disease-free survival compared to those with unamplified genes (P = 0.015,
median follow up 45 months). This correlation was confined to node-negative patients and persisted in
multivariate analysis. No significant correlation to survival from breast cancer was found. It is concluded that
amplification of the II q13 region in breast cancer occurs in a particular subset of aggressive tumours, quite
different from that identified by HER-2/neu amplification. It still remains to be shown that the selection for
amplified genes at I1q13 is due to the activity of INT2, HSTJ or yet another, still unidentified, neighbouring
gene. However, the results are potentially ofclinical value in separating a group of node-negative breast cancer
for more intense treatment.
The putative proto-oncogene INT2 is known as one of
several integration sites for mouse mammary tumour virus
(MMTV), a retrovirus implicated in mammary tumouri-
genesis in certain strains of mice (Nusse, 1988a). INT2
encodes a predicted member of the fibroblast growth factor
(FGF) family of potent mitogens or morphogens involved in
angiogenesis, tissue induction and cell migration (Dickson &
Peters, 1987; Thomas, 1988; Burgess, 1988). The human
INT2 gene has been cloned, found to be 89% homologous to
the mouse INT2, and mapped to chromosome 11q13
(Brookes et al., 1989; Casey et al., 1986). Interestingly,
another proto-oncogene, HSTJ (HSTFI), was localised to
the same chromosomal site and also found to be a FGF
member (Adelaide et al., 1988, Yoshida et al., 1987, 1988a).
HSTI was initially detected as a transforming gene in DNA
from human stomach cancer (Sakamoto et al., 1986), found
virtually identical to the KS oncogene from Kaposis sarcoma
(Delli Bovi et al., 1987), and recently also identified as an
alternative integration site for MMTV in mouse mammary
tumours (Peters et al., 1989). INT2 and HST1 are closely
linked in the mouse genome (Yoshida et al., 1988b) and only
35 kilobasepairs apart in the same transcriptional orientation
in the human genome (Wada et al., 1988). This suggests that
they originated through duplication of a common ancestral
gene during evolution, and that this region may involve still
other, yet unknown, related genes.
Amplification of the 1 1q13 region have been reported from
various solid tumours including, besides breast cancer, squa-
mous cell carcinomas (Zhou et al., 1988, Berenson et al.,
1989), a stomach cancer and the vulvar carcinoma cell line
A431 (Yoshida et al., 1988a), melanomas (Adelaide et al.,
1988, Theillet et al., 1989), bladder and Oesophageal carcin-
omas (Tsutsumi et al., 1988; Tsuda et al., 1988; Theillet et
al., 1989), and a hepatocellular carcinoma (Hatada et al.,
1988). It usually entails the INT2 and HSTJ genes and also
the BCLI locus, recognised as a chromosomal breakpoint in
B-cell leukaemia (Tsujimoto et al., 1984), but not other genes
located at the same or neighbouring bands (Ali et al., 1989).
Multiple endocrine neoplasia type I (MEN-I), the patho-
genesis of which seems to involve a putative FGF-member,
have also been linked to a locus proximal to the INT2 gene
at I Iql2-q13 (Nakamura et al., 1989; Bale et al., 1989).
Consequently, although no evidence yet exists, the plain fact
that both selective amplifications and non-random transloca-
tion encompass the same chromosomal region, points to its
importance in the development of human cancer.
In breast cancer, amplification of the INT2 and HSTI
genes have been found in 9-23% (Zhou et al., 1988, Lide-
reau et al., 1988; Varley et al., 1988; Tsuda et al., 1989;
Theillet et al., 1989; Adnane et al., 1989; Fantl et al., 1989).
When clinical follow-up was available, a correlation to poor
survival was noted. In the present study we report on INT2/
HSTI coamplification in a particular subset of human breast
cancer with hormone-dependent phenotype, and on the cor-
relation to disease outcome among low-risk patient cate-
gories.
Materials and methods
Patients and tumour material
Patients were all from the southern Sweden health care
region, diagnosed for breast disease during the time interval
of October 1982 and February 1985 and had a tumour sent
for steroid receptor analysis. Tumours used for the present
study were consecutive cases with a tissue amount allowing
gene analysis, representing about 25% of all new cases of
breast disease diagnosed during this time period. Cases
ineligible for the study (e.g. benign disease, cancer in situ or
samples from metatases) were excluded, as were tumours
judged to be too cell-poor after cytopathological examination
of tissue imprints. Patients presenting with bilateral cancer
were not excluded if it was clear which primary tumour
recurred.
Of the remaining 311 tumours, 27% were classified accord-
ing to UICC as Stage I, 36% as Stage IIa, 24% as Stage IIb,
7% as Stage III, and 7% as Stage IV (distant spread at
diagnosis or within 2 months after primary operation). Ten
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patients not treated with axillary resection were unclassified.
However, none of these had metastases at diagnosis. The
range of patient age at operation was 31-92 years (median
63 years), 22% were premenopausal and 78% were post-
menopausal. Adjuvant tamoxifen was given to 38% of the
patients, adjuvant chemotherapy (cyclosphosphamide) to 6%,
whereas 45% received postoperative radiation (Sigurdsson et
al., 1990). Recurrences were clinically confirmed and register-
ed as loco-regional or distant. Deaths were distinguished as
due to breast cancer or to intercurrent disease. Distant recur-
rences were found in 94 cases and loco-regional recurrences
in 11 cases. Of 115 deaths, 81 were due to breast cancer.
Median follow-up for all patients was 46 months, for those
still living 53 months, and for those still living or dead in
intercurrent disease 51 months. Only distant recurrences were
considered in the calculation of distant disease-free survival,
which also locoregional recurrences were included in disease-
free survival. Death due to breast cancer was used as end-
point in breast cancer survival and death due to other causes
were censored. Only patients with Stage I-III (MO) disease
were included in the survival analyses.
Results
INT2/HSTI amplification
Hybridisation of the INT2 SS6 probe to BamHI digested
DNA (Figure 1) revealed the known polymorphism of this
locus (two alleles; 8.4 and 5.6/2.8 kb fragments, respectively
(Casey et al., 1986)) and the normal, approximately, 2:1
distribution of alleles among studied tumours. Both alleles
were found affected by amplification but, in tumours heter-
ozygous for the site, in no cases simultaneously. The HST
pORFI probe recognised four constant ECORI digested
DNA fragments (Figure 2). The three shortest fragments
(5.8, 2.8 and 0.8 kb) harbour the HSTJ gene, while the
largest fragment (8.0 kb) represents binding to the HST2
gene (Yoshida et al., 1988a). Amplification was found to
exclusively affect the HSTJ gene.
INT2 amplification was detected in 27 (9%) of 311 slot
blot analysed tumours using the PgR gene as a single copy
standard (Figure 3). The HSTI gene was found to be ampli-
fied in the same 27 tumours and to approximately the same
degree, strongly suggesting that these two related genes are
amplified as one amplicon unit. Degree of amplification
Steriod receptor analysis
Measurements of Oestrogen (ER) and progesterone receptors
(PgR) were performed within two weeks after surgery, at one
laboratory and with radioligand binding techniques (isoelect-
ric focusing and dextran-coated charcoal (DCC) with Scat-
chard analysis, respectively) as described previously (Norgren
et al., 1982). The isoelectric focusing assay has previously
been shown to be eqivalent to the DCC assay for ER
measurement (Ferno et al., 1983). Cut-off points of
10 fmol mg-' protein were used for classification of tumours
as receptor positive or negative.
Gene analysis
DNA was extracted from pulverised tissue (Krieg et al.,
1983) and checked for purity and high molecular weight
integrity. According to fluorometric determination of DNA
concentration, equal amounts (5 gig) of RNAase treated
DNA were applied on Zetaprobe nylon membranes using a
Bio-Dot SF blotting apparatus (BioRad laboratories, Rich-
mond, CA). Ten tig of BamHI or EcoRI digested DNA were
separated in 0.8% agarose gels and transferred to nylon
membranes (Southern, 1975). Membrane hybridisation was
carried out under stringent conditions according to the
manufacturer's description with 106cpm ml-' multiprime
labelled (Amersham International plc, Buckinghamshire,
England) DNA probes. For repeated hybridisation, probes
were removed and membranes checked for absent signals.
The DNA probes used for the study were; INT2 (0.9 kb Sacl
genomic DNA fragment, SS6) HST (0.59 kb AvaI cDNA
fragment, ORFI) and progesterone receptor (2.6 kb BamHI-
PstI cDNA fragment, HPR-54). Degree of amplification was
evaluated with densitometric analysis of short time exposed
slot blot autoradiograms, in comparison with dilutional
analysis of amplified samples and expressed as copies of the
haploid genome. The PgR gene (1 lq22-q23) was used as
internal control for the genes at 1 1q13.
Statistical analysis
The association of gene amplification with other categorised
clinico-pathological variables was assessed by X2-square
analysis. Survival curves were calculated by the method of
Kaplan and Meier (1958). Tests of differences between curves
were made with the log-rank test for censored survival data
(Mantel, 1966). Multivariate analyses were performed with
Cox's partially nonparametric regression model (Breslow,
1975; Cox, 1972). The Biomedical Computer Program P
series (Dixon, 1988) was used in all survival analyses.
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Figure 1 Hybridisation of the INT2 SS6 probe to BamHI
digested breast cancer DNA. A two allele polymorphism is seen;
8.4 and 5.6/2.8 kb, respectively. Amplification of the INT2 gene is
seen in lane 3 (7 copies), lane 4 (3 copies), lane 11 (5 copies), lane
16 (8 copies) and lane 18 (15 copies). A partial rearrangement of
the INT2 gene is seen in lane 16. Lane I shows HindIII digested
lambda phage DNA.





Figure 2 Hybridisation of the HST pORFl probe to EcoRI
digested breast cancer DNA. Bands at 5.8, 2.8 and 0.8 kb repre-
sent binding to the HSTI gene, while the band at 8.0 kb harbours
the HST2 gene. Amplification (3-7 copies) of the HSTI gene is










Figure 3 Hybridisation of the INT2 SS6 probe to a breast
cancer DNA slot blot, and rehybridisation with a PgR HPR-54
probe. INT2 copy numbers of amplified tumours are indicated.
ranged from 2-15 copies; 18 samples having 2-4 copies, 8
samples 5-10 copies, and 1 sample > 10 (15) copies of the
genes.
INT2/HSTI amplification in relation to other prognostic
factors
INT2/HSTI amplification was not statistically correlated
with axillary lymph node status. The tendency of gene ampli-
fication being more prevalent in node positive tumours was
caused by the relatively high incidence of amplification in the
node positive subgroup with few involved nodes. No associa-
tion with tumour size or stage of disease was seen, neither to
patient age or menopausal status (Table I).
However, 26 (96%) of the 27 amplified tumours were ER
positive, compared with 65% of the unamplified cases
(P = 0.001). The ER concentration in amplified tumours was
most often of high levels (>200 fmol/mg-' protein, Figure
4) and, furthermore, the single deviating sample was not
totally devoid of ER, but just below the cut-off value used to
classify tumours as ER positive. A similar trend, although
not significant, was observed with PgR status. Also shown in
Figure 4 is the quite different pattern of ER concentrations in
HER-2/neu amplified tumours. HER-2/neu amplification was
found in 52 (17%) of the 311 cases (Borg et al., 1990). Three
of these were also amplified for the 1 1q13 region and, notice-
ably, also those with the lowest ER concentration among
INT2/HSTI amplified cases.
As not all patients were given postoperative radiation and
the same, or any, adjuvant therapy, a bias might be intro-
duced in the calculation of survival differences. However,
there was no distinction whatever between amplified and
unamplified tumours in respect of therapy. Adjuvant tamox-
ifen, adjuvant chemotherapy and postoperative radiation
were given to, respectively, 12 (44%), 2 (7.4%) and 12 (44%)
of the 27 amplified tumours, and to, respectively, 106 (37%),
18 (6.3%) and 127 (45%) of the 284 unamplified tumours.
INT2/HSTI amplification in relation to survival
INT2/HSTI amplification was found to be a significant pre-
dictor of a shorter disease-free survival (DFS, P = 0.015)
when analysing all MO patients (n = 291, Figure 5a). There
was a trend towards a worse prognosis of tumours with a
Table I INT2/HSTJ amplification in relation to other categorised
prognostic factors
Variable Amplified/total (%) P-value
Node status
Negative 10/161 (6%)
Positive 16/139 (12%) P= 0.10
No. of positive nodes
1-3 12/72 (17%)
4-10 3/53 (6%)
> 10 1/14 7%) P= 0.14
Tumour size
<2 cm 10/118 (8%)
2-5 14/163 (9%)






IV 2/20 (10%) P = 0.36
Menopause
Pre 6/68 (9%)
Post 21/243 (9%) P= 0.96
ER
<10 1/99 (1%)
" 10 26/212 (12%) P= 0.001
PgR
<10 8/123 (6%)
" 10 18/171 (10%) P= 0.23
HER-2/neu
Single copy 23/258 (9%)
Amplified 3/52 (6%) P=0.46
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Figure 4 Oestrogen receptor concentrations in breast cancers
containing a single and amplified copy number of the INT2/
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Figure 5 Relationship between INT2/HSTJ amplification and
disease-free survival a, or breast cancer survival b in a MO
patients (n = 291).
high copy number () 5 copies) compared to those with a low
degree of amplification (6 recurrences in 8 cases compared to
7 in 17 cases). Of a total of 13 recurrences in the 25 included
amplified tumours, 3 were of loco-regional type while 10 were
distant metastases. Thus, the calculation of amplification in
relation to distant DFS resulted in a less prominent associa-
tion (P = 0.12). Neither did the prediction of breast cancer
survival (P = 0.19, Figure Sb) reach significance.
The presence of axillary lymph node metastases is widely
considered as the most reliable risk factor in breast cancer,
and it was natural to perform separate analyses of gene
amplification in relation to survival in the node-negative and
node-positive patient subgroups. As revealed in Figure 6, the
significance of INT2/HSTI amplification as a predictor of
DFS was totaly confined to the node-negative group (P =
0.030, n = 160). No association was seen in node-positive
patients (P = 0.73, n = 120). The corresponding correlations
in node-negative patients to distant DFS (P = 0.092) or
breast cancer survival (P = 0.21) were, again, not statistically
significant.
As INT2/HSTI amplification affected mainly ER positive
tumours, this category was analysed separately (Figure 7). A
highly significant correlation (P = 0.002) was found to a
shorter DFS in amplified ER positive tumours as compared
with unamplified ER positive tumours. ER negative tumours
had an intermediate DFS pattern (Figure 7). In the ER
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Figure 6 Relationship between INT2/HSTJ amplification and
disease-free survival in node-negative and node-positive MO
breast cancer patients.
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Figure 7 Relationship between INT2/HSTI amplification and
disease-free survival in ER positive MO breast cancer. Also shown
is the disease-free survival for ER negative. MO breast cancer.
positive category, amplification was significantly or nearly
significantly correlated also to distant DFS (P = 0.026) and
breast cancer survival (P = 0.070).
To examine the significance of INT2/HSTI amplification
as a predictor of DFS in combination with other prognostic
factors, multivariate analyses (Table II) were performed on
all MO patients (actually 264, since lymph node status and
PgR status were unavailable in 10 and 16 cases, respectively)
as well as on node-negative patients separately (n = 148, PgR
status not available in 12 cases). When analysing all MO
patients, lymph node status was the single most powerful
predictor of DFS, followed by PgR status and tumour size.
INT2/HSTI amplification was retained in the model as a
nearly significant variable (P = 0.060) with a relative risk of
1.7 for amplified tumours. In node-negative patients, PgR
status and INT2/HSTI amplification were the only and
approximately equally significant independent variables (P =
0.011 and P = 0.013, respectively), with a relative risk of 4.0
(95% confidence interval 1.3-12) for amplified tumours. It
should be pointed out that the number of tumours and
events in some analyses are small and that the results of these
must be cautiously interpreted.140 A. BORG et al.
Table II INT2/HSTJ amplification in relation to other prognostic factors for prediction ofdisease-free
survival in all MO and in node-negative breast cancer patients
Disease-free survival Disease-free survival
All MO patients (n = 264) Node-negative patients (n = 148)
Factor Univariate Multivariate Relative Univariate Multivariate Relative
P-value P-value risk P-value P-value risk
Lymph node status <0.0001 <0.0001 1.5 - -
(1.3-1.7)
Tumour size <0.0001 0.0009 2.6 0.027 0.10
(1.5-4.5)
Oestrogen receptor 0.14 0.14 - 0.43 0.58
Progesterone receptor <0.0001 0.0001 2.4 0.019 0.011 2.8
(1.5-3.8) (1.3-6.3)
Menopausal status 0.14 0.49 - 0.68 0.70 -
INT2/HSTJ amplification 0.079 0.060 1.9 0.033 0.013 4.0
(1.0-3.5) (1.3-12)
The multivariateanalyses wereperformed with Cox'smodel, with thevariablesenteredstepwise. Relative
risks are presented only for retained variables. Values in parentheses are 95% confidence intervals. Factors
were categorised as: Lymph node status (0 vs 1 -3 vs > 3 positive nodes); Tumour size ( <2 vs >2 cm);
Oestrogen receptor (>10 vs <10 fmol/mg protein); Progesterone receptor (>10 vs <10 fmol/mg
protein); Menopausal status (post vs pre); INT2/HSTJ amplification (single copy vs amplified).
Discussion
The ability of cancer cells to increase their content of certain
macromolecules by gene amplification in response to environ-
mental stress or intratumoural competitive growth, is well
established (Schimke, 1984). In cytogenetic studies of tumour
cells grown for short terms to avoid in vitro artefacts, ampli-
fied DNA is seen mainly as extrachromosomal chromatin
bodies in forms of double minutes or their precursors (Wahl,
1989). These genetic aberrations replicate autonomously, but
lack centromers and are supposed to be randomly distributed
during cell division and ultimately lost if not providing a
selective growth advantage. The frequent finding of proto-
oncogene amplification in human breast cancer point to its
role in disease development. At least three different chromo-
somal regions are commonly affected; entailing the HER-2/
neu and ERBAI genes at 17qll.2-ql2, the MYC gene at
8q24, and the INT2/HSTI genes at 1lql3 (Callahan, 1989).
The present study suggests that amplification of the 1 1q13
region in breast cancer occurs in a quite different subset of
tumours than affected by HER-2/neu amplification, a con-
clusion also drawn by Adnane et al. (1989). In contrast to
HER-2/neu amplification, INT2/HSTJ amplification was not
associated with tumour size, an increased number of involved
lymph nodes or distant spread. Furthermore, while HER-2/
neu amplification was strongly connected with the absence of
steroid receptors and probably with an autonomous growth,
INT2/HSTI amplification occurred exclusively in ER positive
tumours. This implies an importance of INT2/HSTI in ear-
lier stages of certain breast cancers and that an interaction
with or a dependence of Oestrogen stimulation may exist.
Tumour progression to decreased hormone sensitivity would
then be reflected in the loss of unstable genetic aberrations
no longer involved in growth regulation, or in the over-
growth of other cell clones within the same tumour. Alterna-
tively, one could consider ER positive and negative tumours
as subsets of breast cancer rather than successive progression
stages. INT2/HSTI and HER-2/neu amplification may then
represent two pathways to reach this difference from a com-
mon precursor cell type, or be indicative of the presence of
two different original cells.
The PgR gene, one of the major targets of Oestrogen
action, was in an initial report (Law et al., 1987) mapped to
the same chromomsomal site as INT2. The location of the
PgR gene was, however, later revised to a more distal site on
the long arm (1lq22-q23, Rousseau-Merck et al., 1987, Mat-
tei et al., 1988). The PgR gene was in the present study also
found in no case to be coamplified with the genes at 1q13.
No evidence exists as yet for a specific physiological role of
INT2 or HSTJ in humans. An activity of the genes during
mesoderm induction was, however, demonstrated in amphib-
ian embryos (Paterno et al., 1989). Mouse HSTJ was found
expressed during a short interval in midstage embryos
(Terada et al., 1989). The normal activity of INT2 in mice is
also confined to the early embryonic development, where a
stimulation of cell migration and tissue induction rather than
of cell proliferation and angiogensis was suggested (Wilkin-
son et al., 1989). Its reactivation in the adult mouse mam-
mary gland by inserted proviral enhancers points to a
causative role in the subsequent neoplastic formation. Inter-
estingly, these tumours are initally hormone-dependent in
that they arise only after several pregnancy cycles and regress
between pregnancies. When tumours eventually progress to
become autonomous, this seems to occur irrespective of fur-
ther INT2 activity (Peters et al., 1984; Nusse, 1988b). A
similar synergism between INT2 or HSTI and sex hormones
in the earlier development of certain human breast cancers is
conceivable, the former acting as inducers and the latter as
promoters.
Arguing against this is the fact that INT2/HSTI ampli-
fication is found also in other malignancies in general con-
sidered not to be hormone-responsive. Also, it still remains to
be confirmed that amplification of the genes actually coincides
with a transcriptional activation, a controversial subject in
human breast cancer: Liscia et al. (1989) used RNA:RNA in
situ hybridisation and Northern blot analysis to show that
some INT2/HSTJ amplified tumours contained INT2, but not
HSTI, transcripts, implying that INT2 is the probable gene of
significance in the amplicon. Several mRNA species of
different sizes (2.4-4.6 kb) were observed (Liscia et al., 1989),
none however equivalent to the single 1.7 kb INT2 transcript
detected in teratocarcinoma cell lines and predicted from the
physical map of the INT2 gene (Fantl et al., 1989). On the
contrary, Theillet et al. (1989) saw both INT2 and HSTI
transcripts with RNA:RNA in situ hybridisation, but found
connection to gene amplification only in the case of HSTI.
Moreover, Fantl et al. (1989), using a sensitive RNAase
protection assay to analyse both INT2 amplified and unamp-
lified tumours, were unable to detect any expression of INT2
or HSTI and suggested that another gene in the vicinity of
INT2 may be ofimportance. Terada et al. (1989), analysing a
variety of cancerous and non-cancerous human cells and
tissues for HSTI transcripts, also reported on negative find-
ings except in some cases of testicular germ-cell tumours and
a teratoma cell line. It must however be remembered that
even a low level of expression of normally silent genes may
be sufficient to induce aberrant growth. Neither can it be
excluded that the findings of gene amplification in these
clinical tumours is a reminiscence of an earlier activity.
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shown to be associated with a poor clinical outcome (Lider-
eau et al., 1988; Zhou et al., 1988; Tsuda et al., 1989). A
prognostic value of gene amplification in prediction of
disease-free survival was confirmed in the present study,
found to persist in multivariate analysis and to be confined to
node-negative patients. A subset of these latter patients, a
group in general considered as being of good prognosis,
could be separated and shown to have a disease-free survival
as bad as node-positive patients. At this median time of 46
months follow-up, the correlations had not yet translated
into survival differences. As the number of cases and relapse
events in the node-negative group are small, the results must
be critically interpreted. However, if shown to be valid in
future investigations, amplification of this chromosomal
region may become an important prognostic factor and use-
ful in selection of node-negative patients for adjuvant
therapy. Also, an increased knowledge of the genes at 1 1q13
will most certainly contribute to a deeper understanding of
human breast cancer etiology.
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